Please try another search
Pila Pharma AB is a Sweden-based clinical stage pharmaceutical company, active in the biotechnology sector. The Company conducts clinical tests in phase 2 with drugs against type 2 diabetes. The target product is a tablet that is taken orally in an early stage of diabetes to restore the body's insulin production and thereby reduce the patient's blood sugar level. PILA PHARMA's patent-protected product candidate is called XEN-D0501 and is a TRPV1 antagonist, a novel type of oral anti-diabetic agent for treatment of type 2 diabetes. Pila Pharma AB has completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes. In addition, the product is expected to have fewer unwanted side effects than alternative forms of treatment.
Name | Age | Since | Title |
---|---|---|---|
Lasse Richter Petersen | - | 2024 | Director |
Dorte Xenia Gram | 55 | 2014 | Founder, Chairman & Chief Scientific Officer |
Mark Evans | - | 2020 | Member of Scientific Advisory Board |
Richard Busellato | 57 | 2023 | Director of the Board |
Arpad Szallasi | - | 2013 | Member of Scientific Advisory Board |
Bo Ahren | - | 2013 | Member of Scientific Advisory Board |
Jens Juul Holst | - | 2013 | Member of Scientific Advisory Board |
Jens Viktor Norgaard | - | 2016 | Member of Scientific Advisory Board |
Carolyn F. Deacon | - | 2013 | Member of Scientific Advisory Board |
Soren Weis Dahl | 58 | 2023 | Director of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review